Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis

British Journal of Haematology

Volumn 116, Issue 4, 2002, Pages 855-861

  Passamonti, Francesco ^a   Malabarba, Lucia ^a   Orlandi, Ester ^a   Pascutto, Cristiana ^a   Brusamolino, Ercole ^a   Astori, Cesare ^a   Baratè, Claudia ^a   Canevari, Angelo ^a   Corso, Alessandro ^a   Bernasconi, Paolo ^a   Cazzola, Mario ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Chronic myeloproliferative disorders; Essential thrombocythaemia; Pipobroman; Second malignancies; Thrombosis

Indexed keywords

PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MYELOFIBROSIS; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELOFIBROSIS; NEOPLASMS; PIPOBROMAN; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS; TREATMENT OUTCOME;

EID: 0036121982     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0007-1048.2002.03367.x     Document Type: Article

References (35)

1. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment
2. Clinical parameters for determining when and when not treat essential thrombocythemia
3. Essential thrombocythemias: Clinical evolutionary and biological data
4. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group
5. Therapeutical recommendations in polycythemia vera based on Polycythemia Vera Study Group
6. Efficacy trial of pipobroman in essential thrombocythemia: A study of 24 patients
7. Essential thrombocythemia: A retrospective study on the clinical course of 100 patients
8. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
9. Hydroxyurea for patients with essential thrombocythemia and high risk of thrombosis
10. Clinical course of essential thrombocythemia in 147 cases
11. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial
12. Epi-demiological, diagnostic, therapeutic and prognostic aspects of essential thrombocythemia in a retrospective study of the GIMMC group in two thousand patients
13. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia
14. Interferon alpha-2b as a treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis
15. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea
16. Pipobroman therapy of essential thrombocythaemia
17. Therapy related myelo-dysplastic syndrome and acute myeloid leukemia with 17p deletion. A report of 25 cases
18. Myelodysplasic transformation in a case of essential thrombocythemia treated with pipobroman
19. Essential thrombocythemia: An interim report from the Polycythemia Vera Study Group
20. Experience of Polycythemia Vera Study Group with essential thrombocythe-mia: A final report on diagnostic criteria, survival, and leukemic transition by treatment
21. Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years
22. Efficacy of pipobroman in the treatment of polycythemia vera: Long term results in 163 patients
23. Primary thrombocythaemia: Diagnosis and management
24. Anagrelide, a novel platelets lowering option in essential thrombocythemia: Treatment experience in 48 patients in Germany
25. Leukemia and mye-lodysplasia in patients with essential thrombocythemia treated with cytotoxic agents
26. Life expectancy of patients with chronic nonleukemic myelo-proliferative disorders
27. No treatment for low-risk thrombocythaemia: Results from a prospective study
28. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p- deletion
29. Long-term use of anagrelide in young patients with essential thrombocythemia
30. A long term retrospective study of young women with essential thrombocythemia
31. Primary thrombo-cythaemia treated with busulphan
32. Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin
33. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors